Marien Hospital Duesseldorf GmbH — Clinical Trial Site

38 Registered trials

15 Currently recruiting

Organisation

Marien Hospital Duesseldorf GmbH

Location

Duesseldorf, Germany

Identifier

ORG-100024583

Address

Rochusstraße 2, Pempelfort, 40479, Germany

Departments

" Klinik für Hämato-Onkologie"
127601
Clinic for Oncology, Haematology and Palliative Medicine
Hämatologie und Palliativmedizin
Hematology
Hematology and Oncology
Klinik fuer Onkologie, Haematologie und Palliativmedizin
Klinik für Onkologie / Hämatologie und Palliativmedizin
Klinik für Onkologie und Hämatologie
Klinik für Onkologie und Hämatologie, Palliativmedizin Hämatologisches Speziallabor
Klinik für Onkologie, Hämatologie und Palliativmedizin
Klinik für Onkologie, Hämatologie und Palliativmedizin
Klinik für Onkologie, Hämatologie, und Palliativmedizin
Klinik für Viszeral-, Minimalinvasive und Onkologische Chirurgie
Marien Hospital Duesseldorf Klinik für Onkologie, Haematologie und Palliativmedizin
Marien Hospital Düsseldorf Klinik für Onkologie, Hämatologie und Palliativmedizin
Oncology, hematology and palliative care
Onkologie, Hämatologie und Palliativmedizin
Onkologiezentrum

Clinical trials at this site (38)

Search interface

A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i… Ended

2023-509859-13-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-11-09
IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combinatio… Ended

2023-506854-19-00 Solid Tumors 1 2022-05-19
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myel… Ended

2023-507469-24-00 Anemia in Patients with Very Low, Low, or Intermediate 4 2022-04-30
Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa… Ended

2024-518304-53-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-02-02
Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-D… Ended

2024-517761-17-00 Multiple Myeloma 4 2021-05-31
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter… Ended

2022-501485-22-00 Myelodysplastic syndrome (MDS) 5 2018-12-18
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEA… Ended

2024-515619-23-00 essential thrombocythemia 4 2015-06-29
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia Ended

2023-508819-23-00 Primary immune thrombocytopenia (ITP) 3 2024-07-24
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffus… Ended

2023-508259-38-00 Adult patients with relapsed or primary refractory DLBC 5 2021-04-29
Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Ended

2024-513313-13-00 Acute Myelogenous Leukemia (AML) or higher-risk Myelody 9 2020-12-09
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Generalized mantle cell Lymphoma 5 2016-07-25